Key result
MicroRNAs show potential as biomarkers for diagnosis and prognosis and as therapeutical targets in hypertrophic cardiomyopathy.
This review highlights the emerging role of miRNAs as diagnostic biomarkers and potential therapeutic targets in the management of hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease characterized by variable expressivity, age penetrance, and a high heterogeneity. The transcriptional profile (miRNAs, mRNAs), epigenetic modifications, and posttranslational modifications seem to be highly relevant for the onset of the disease. miRNAs, small noncoding RNAs with 22 nucleotides, have been implicated in the regulation of cardiomyocyte function, being differentially expressed in several heart diseases, including HCM. Moreover, a different miRNA expression profile in the various stages of HCM development is also observed. This review summarizes the current knowledge of the profile of miRNAs characteristic of asymptomatic to overt HCM patients, discussing alongside their potential use for diagnosis and therapy. Indeed, the stability and specificity of miRNAs make them suitable targets for use as biomarkers for diagnosis and prognosis and as therapeutical targets.
No takes yet. Share an insight, caveat, or question.
Roma‐Rodrigues et al. (2015) conducted a review in Hypertrophic cardiomyopathy (HCM). MicroRNAs (miRNAs) was evaluated. MicroRNAs show potential as biomarkers for diagnosis and prognosis and as therapeutical targets in hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: